Thomas Mitchell, MD
Internal Medicine · Asheville, NCNPI 1376751909
Payments from drug & device makers
Across 154 payments — averaging $42.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tandem Diabetes Care, Inc.$4K
- Medtronic$363
- Amgen$292
- Johnson & Johnson$273
- Insulet Corporation$229
- Abbott$208
- plus $1K from 21 others
What the payments were for
- Speaking & faculty fees$4,15063%
- Food & beverage$2,44237%
- Education$50%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tandem Diabetes Care, Inc. | 15 | $4,191 |
| Medtronic(2 entities) | 13 | $363 |
| Amgen | 15 | $292 |
| Johnson & Johnson | 40 | $273 |
| Insulet Corporation | 6 | $229 |
| Abbott | 10 | $208 |
| Lilly USA, LLC | 8 | $158 |
| Novo Nordisk | 6 | $104 |
| Cequr Corporation | 3 | $102 |
| Xeris Pharmaceuticals, Inc. | 4 | $78 |
| Boehringer Ingelheim | 5 | $66 |
| Dexcom, Inc. | 3 | $63 |
| Corcept Therapeutics | 4 | $61 |
| Bayer | 3 | $60 |
| AstraZeneca(2 entities) | 4 | $55 |
| BETA Bionics, Inc. | 2 | $46 |
| IBSA Pharma Inc. | 2 | $37 |
| Nevro Corp. | 2 | $37 |
| Senseonics, Incorporated | 1 | $29 |
| Gilead | 1 | $27 |
| Sanofi-aventis U.S. LLC | 1 | $25 |
| Astellas Pharma US Inc | 1 | $20 |
| Antares Pharma, Inc. | 1 | $17 |
| Lifescan, Inc. | 1 | $15 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| AbbVie | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t:slim X2 insulin pump$3,000
- t-slim insulin pump$1,150
- Omnipod$118
- MINIMED 770G$102
How this compares
$6,598 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 502 | $799,196 |
| MounjaroTirzepatide | 303 | $455,004 |
| JardianceEmpagliflozin | 359 | $383,351 |
| TrulicityDulaglutide | 89 | $157,363 |
| FarxigaDapagliflozin Propanediol | 128 | $145,174 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 105 | $137,510 |
| Tresiba Flextouch U-100Insulin Degludec | 174 | $122,193 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 74 | $86,433 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 103 | $83,498 |
| Novolog FlexpenInsulin Aspart | 225 | $82,588 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 79 | $82,092 |
| JanuviaSitagliptin Phosphate | 67 | $66,747 |
| Humalog Kwikpen U-200Insulin Lispro | 20 | $65,014 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 50 | $61,648 |
| RybelsusSemaglutide | 34 | $59,373 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $104 | $891,213612 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $158 | $630,059460 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $66 | $465,443438 claims |
| AstraZenecaFarxiga | $55 | $145,174128 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $25 | $54,25958 claims |
| Antares Pharma, Inc.Xyosted | $17 | $12,95614 claims |
| AbbVieSynthroid | $14 | $9,946108 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Asheville
- Manesh PatelDurham$27.2M
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- John RubinoRaleigh$13M
- Adam DevoreDurham$11.8M
- Krishnakumar UdayakumarDurham$11M
- Sylvia ShoffnerCary$7.1M
- Wayne HarperRaleigh$6.7M
- Joseph MoranStatesville$6.7M
- April SalamaDurham$6.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.